Clinical Trials · NCT00372697
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 28
- Start date
- Dec 2005
- Locations
- 1 site, Italy
- Primary endpoint
- Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24)